Oral COTI-2 Plus Doxil(R) Is Superior To Doxil Alone In An Animal Model Of Human Ovarian Cancer

Main Category: Ovarian Cancer
Also Included In: Cancer / Oncology;  Women's Health / Gynecology
Article Date: 19 Aug 2009 - 4:00 PDT

email to a friend   printer friendly   opinions  

Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) announced important positive results today from a series of experiments carried out at a prominent American cancer research facility. The experiments were designed; first, to estimate the oral maximum tolerated dose (MTD) for COTI-2; second, to evaluate the effectiveness of oral COTI-2 alone and third, to compare the effectiveness of oral COTI-2 plus Doxil® (doxorubicin HCl) to that of Doxil alone. The experiments showed that:

- The MTD from these experiments is 100-125 mg/kg when COTI-2 is given once daily for 5 days/week for up to three consecutive weeks.

- The maximum tumor growth inhibition was 62.8% (p less than 0.05) at day 19 in animals treated with COTI-2 at or below the MTD compared with animals receiving no drug treatment.

- The maximum tumor growth inhibition was 79.2% (p less than 0.05) at day 19 in animals treated with COTI-2 at or below the MTD plus Doxil compared with animals receiving no drug treatment.

- The maximum tumor growth inhibition was 80.2% (p less than 0.05) at day 19 in animals treated with COTI-2 at or below the MTD plus Doxil compared with animals treated with Doxil alone.

- Treatment with the combination of COTI-2 and Doxil was well tolerated.

These results confirm and extend results from previous animal experiments where COTI-2 was given intravenously and provide strong supportive evidence for the continued development of oral COTI-2 in combination with conventional single agent therapy for the treatment of human ovarian cancer.

"COTI-2 was originally designed to be an oral agent for the out patient treatment of multiple cancers and we are delighted to see that oral COTI-2 alone, and in combination with Doxil, showed superior treatment results compared to Doxil alone as measured by significant tumor growth inhibition in an animal model of an aggressive human ovarian cancer (A2780). These results are significant because they add to the impressive data set of COTI-2, showing effectiveness, particularly in combination with first and second line agents, against multiple cancers while also exhibiting low toxicity," said Dr. Wayne R. Danter, President and Chief Scientific Officer of COTI.

"We are very pleased to receive this important new scientific data providing powerful evidence supporting the commercial potential of our pipeline," said Mr. Michael Cloutier, Chief Executive Officer of COTI.

Source
Critical Outcome Technologies Inc. (COTI)

• Additional
• References
• Citations